Multitargeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials

    Li Zhang
    Li Zhang

    Journal of Clinical Oncology, 2017.

    Cited by: 0|Bibtex|Views0|

    Abstract:

    8089 Background: Novel multitargeted antiangiogenic tyrosine kinase inhibitors (MATKIs) have showed promising advantages in combination with chemotherapy or as monotherapy in treatments of advanced non-small cell lung cancer (NSCLC). Since the efficacy and safety of these small molecules have been evaluated by several phase II/III randomi...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments